- Latest available (Revised)
- Point in Time (31/01/2020)
- Original (As adopted by EU)
Regulation (EC) No 1394/2007 of the European Parliament and of the CouncilShow full title
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 (Text with EEA relevance)
You are here:
What Version
Advanced Features
- Show Geographical Extent(e.g. England, Wales, Scotland and Northern Ireland)
- Show Timeline of Changes
More Resources
Revised version PDFs
- Revised 26/07/20190.30 MB
- Revised 02/07/20120.25 MB
- Revised 30/12/20070.10 MB
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Changes over time for: ANNEX II
Alternative versions:
Status:
Point in time view as at 31/01/2020.
Changes to legislation:
There are outstanding changes not yet made to Regulation (EC) No 1394/2007 of the European Parliament and of the Council. Any changes that have already been made to the legislation appear in the content and are referenced with annotations.
Changes to Legislation
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
ANNEX IIU.K.Summary of product characteristics referred to in Article 10
1.Name of the medicinal product.U.K.
2.
Composition of the product:U.K.
2.1.general description of the product, if necessary with explanatory drawings and pictures,U.K.
2.2.qualitative and quantitative composition in terms of the active substances and other constituents of the product, knowledge of which is essential for proper use, administration or implantation of the product. Where the product contains cells or tissues, a detailed description of these cells or tissues and of their specific origin, including the species of animal in cases of non-human origin, shall be provided,U.K.
For a list of excipients, see point 6.1.
3.Pharmaceutical form.U.K.
4.
Clinical particulars:U.K.
4.1.therapeutic indications,U.K.
4.2.posology and detailed instructions for use, application, implantation or administration for adults and, where necessary, for children or other special populations, if necessary with explanatory drawings and pictures,U.K.
4.3.contra-indications,U.K.
4.4.special warnings and precautions for use, including any special precautions to be taken by persons handling such products and administering them to or implanting them in patients, together with any precautions to be taken by the patient,U.K.
4.5.interaction with other medicinal products and other forms of interactions,U.K.
4.6.use during pregnancy and lactation,U.K.
4.7.effects on ability to drive and to use machines,U.K.
4.8.undesirable effects,U.K.
4.9.overdose (symptoms, emergency procedures).U.K.
5.
Pharmacological properties:U.K.
5.1.pharmacodynamic properties,U.K.
5.2.pharmacokinetic properties,U.K.
5.3.preclinical safety data.U.K.
6.
Quality particulars:U.K.
6.1.list of excipients, including preservative systems,U.K.
6.2.incompatibilities,U.K.
6.3.shelf life, when necessary after reconstitution of the medicinal product or when the immediate packaging is opened for the first time,U.K.
6.4.special precautions for storage,U.K.
6.5.nature and contents of container and special equipment for use, administration or implantation, if necessary with explanatory drawings and pictures,U.K.
6.6.special precautions and instructions for handling and disposal of a used advanced therapy medicinal product or waste materials derived from such product, if appropriate and, if necessary, with explanatory drawings and pictures.U.K.
7.Marketing authorisation holder.U.K.
8.Marketing authorisation number(s).U.K.
9.Date of the first authorisation or renewal of the authorisation.U.K.
10.Date of revision of the text.U.K.
Options/Help
Print Options
PrintThe Whole Regulation
PrintThis Annex only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
See additional information alongside the content
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
Timeline of Changes
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.